Ushering in a new class of antibiotics, the U.S. FDA approved GSK plc’s gepotidacin ... In both the Eagle-2 and Eagle-3 phase III trials, Blujepa demonstrated noninferiority to nitrofurantoin, an ...

Gepotidacin is the first new class of oral antibiotics for uUTIs in nearly 30 years, addressing rising drug resistance. Phase 3 trials showed gepotidacin's non-inferiority to nitrofurantoin ...

Blujepa (gepotidacin) is the first new antibiotic class approved in nearly 30 years ... In these studies, Blujepa was compared with nitrofurantoin, a leading treatment for uncomplicated UTIs.

Blujepa sets itself apart from nitrofurantoin as ... To put it simply, the drug is designed to specifically inhibit bacterial DNA in the E. coli class, which causes the majority of UTI infections ...

In the EAGLE-3 experiment, gepotidacin was statistically superior to nitrofurantoin. “As a first-in-class investigational oral antibiotic with activity against common uropathogens, including ...

Results of two phase III trials -- EAGLE-2 and EAGLE-3-- supported approval, demonstrating that the first-in-class antibiotic was noninferior to nitrofurantoin, a standard option for uncomplicated ...

Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial ... to receive gepotidacin 1500mg twice daily or nitrofurantoin 100mg twice daily for 5 days.

47% in patients treated with nitrofurantoin ... the first in a new class of oral antibiotics for uUTIs in nearly three decades, and to bring another option to patients given recurrent infections ...

Blujepa is part of a new class of antibiotics called triazaacenaphthylenes ... compared to 43% to 47% in a group that received the antibiotic nitrofurantoin. More than half of women will ...

Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes.